Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies

OncoImmunology

Volumn 4, Issue 7, 2015, Pages 1-3

  Omokoko, Tana ^a,b   Simon, Petra ^a,b   Türeci, Özlem ^a   Sahin, Ugur ^a,b,c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BIONTECH AG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Adoptive cell transfer; Epitope; Personalized immunotherapy; T cell engineering; T cell receptor

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; DENDRITIC CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HLA SYSTEM; HUMAN; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION;

EID: 84944454934     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1005523     Document Type: Article

References (10)

1. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013; 13:525-41; PMID:23880905; http://dx.doi.org/ 10.1038/nrc3565
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/ NEJMoa1103849
3. Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013; 31:999-1008; PMID:24142051; http://dx.doi.org/ 10.1038/nbt.2725
4. Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K, et al. Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes. Cancer Immunol Res 2014; 2:1230-44; PMID:25245536; http://dx.doi.org/10.1158/2326-6066.CIR-14-0108
5. Wolfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281-4; PMID:7652577; http://dx. doi.org/10.1126/science. 7652577
6. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81; PMID:25428507; http://dx.doi.org/ 10.1038/nature13988
7. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99; PMID:25409260; http://dx.doi.org/ 10.1056/NEJMoa1406498
8. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx.doi. org/10.1126/science.1251102
9. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al. Cancer exome analysis reveals a Tcell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; http://dx. doi.org/10.1038/nature10755
10. Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081-91; PMID:22237626; http://dx.doi.org/10.1158/0008-5472.CAN-11-3722